What was studied?
A randomized phase 3 trial enrolled 475 adults whose type 2 diabetes remained inadequately controlled on insulin glargine, with or without metformin. Tirzepatide or placebo was added, and the primary outcome was HbA1c change at 40 weeks.
What did the researchers report?
Adding tirzepatide produced greater HbA1c reductions than adding placebo to the titrated insulin regimen. Body weight and glucose-control thresholds were also assessed, alongside adverse events and treatment discontinuation.
What are the limits?
An add-on design estimates an effect within a specified background-treatment strategy. It does not establish that a substance can replace insulin, and it is not a personal-use combination recommendation. Selected participants, monitoring and pharmaceutical formulation limit transfer to other contexts.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.